Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor.

Current cancer drug targets - 1 Jul 2013

Yao Hang-Ping, Zhuang Chun-Mei, Zhou Yong-Qing, Zeng Jun-Ying, Zhang Rui-Wen, Wang Ming-Hai

Abstract excerpt

Aberrant expression of the RON receptor tyrosine kinase contributes to breast cancer malignancy. Although clinical trials of RON targeting are underway, the intriguing issue is the diversity of RON expression as evident by cancer cells expressing different variants including oncogenic RON160. The current study determines aberrant RON160 expression in breast cancer and its potential as a target for breast cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Induction
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphatic Metastasis

Share to Mammary Glands, Human

Share to Random Allocation

Share to Receptor Protein-Tyrosine Kinases

Share to Sulfones

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 23597200
DOI: 10.2174/15680096113139990038

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor.PMID 23597200Read ↗

Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers.Semantic proximity Read ↗

Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential.Semantic proximity Read ↗

Alterations in a defined extracellular region of the RON receptor tyrosine kinase promote RON-mediated motile and invasive phenotypes in epithelial cells.Semantic proximity Read ↗

Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addictionSemantic proximity Read ↗

A novel variant of the RON receptor tyrosine kinase derived from colorectal carcinoma cells which lacks tyrosine phosphorylation but induces cell migration.Semantic proximity Read ↗

Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160.Semantic proximity Read ↗

TMEM160 Promotes Tumor Growth in Lung Adenocarcinoma and Cervical Adenocarcinoma Cell LinesSemantic proximity Read ↗

The pathological significance of abnormal RON and PD-L1 expression in colorectal cancerSemantic proximity Read ↗

Integrative genomic analyses of recepteur d'origine nantais and its prognostic value in cancer.Semantic proximity Read ↗

An Introduction and Overview of RON Receptor Tyrosine Kinase SignalingSemantic proximity Read ↗

Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice.Semantic proximity Read ↗

LYN Is a Mediator of Epithelial-Mesenchymal Transition and a Target of Dasatinib in Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.